Dental group receives takeover bid at a handy premium

This ASX-listed dental group looks likely to be taken over under a new offer.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Pacific Smiles has received a takeover offer at a 37.5% premium.
  • An independent board committee has recommended shareholders accept the offer.
  • The bidder already owns almost 90% of the company's shares.

ASX-listed dental company Pacific Smiles Group Ltd (ASX: PSQ) has received a takeover bid from its majority shareholder, Genesis Bidco, at a 37.5% premium to the share price prior to the bid announcement.

The bidder, which currently owns 89.27% of Pacific Smiles, has offered $2.20 in cash for each share in the company it doesn't already own, compared with the closing price on Thursday of $1.60.

Pacific Smiles has established an independent committee to assess the bid, and that committee has unanimously recommended that shareholders accept the offer in the absence of a superior bid.

The committee has also commissioned an independent expert's report into the bid, to assess whether it is fair and reasonable; however, the company said Deloitte Corporate Finance, which would produce the report, at this stage concluded that the bid was in the best interests of shareholders.

The independent board committee has carefully considered the offer to assess whether it is in the best interest of Pacific Smiles shareholders other than Genesis Bidco and its associates and, having completed that work, unanimously recommends that shareholders accept the offer.

The takeover offer is unconditional and is not subject to regulatory approval.

Businesswoman holds hand out to shake.

Image source: Getty Images

Takeover virtually a fait accompli

The company stated in its ASX announcement on Friday that a competing bid was highly unlikely, given the dominance of the majority shareholder and the fact that the next largest shareholder held a 10.01% stake in the company.

This meant the remaining shareholders own just 0.72% of Pacific Smiles.

The company in August reported an underlying profit of $11.8 million for FY25, up from $8.5 million the previous year, on revenue of $196 million, up 9.1%.

The company spent $11.6 million during the year responding to two previous takeover offers from Genesis Bidco and another vehicle, NDC Bidco, with the money allocated to legal fees and external consulting.

The earlier Genesis takeover offer was launched in July last year and offered $1.90 per share for the company, or a combination of cash and stock in the bidding company.

Pacific Smiles shareholders voted against the NDC proposal at a meeting held in August last year. NDC then walked away from the bidding process, and Genesis relaunched its offer and started building up its stake in the company.

Pacific Smiles shares are thinly traded, with an average trade volume of about 1500 shares.

The company was valued at $258.6 million at the close of trade on Thursday.

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

cochlear happy, share price rise, up, increase
Healthcare Shares

Cochlear share price rebounds 53% from 10-year low: Can it keep climbing?

The shares are still down 47% for the year to date.

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

Two broker upgrades put CSL shares back in focus

CSL is back on the radar after two broker upgrades.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Could this ASX biotech really jump more than 150%? One broker thinks so

A key clinical trial could be a big catalyst for this company.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Cochlear vs Pro Medicus: Which beaten-down ASX healthcare share is the better buy today?

We compare Cochlear and Pro Medicus after major share price declines. See which ASX healthcare stock I’d lean towards today.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Are Telix shares a buy after its big US FDA news?

Telix announced some big news this week.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

These 2 ASX healthcare shares just jumped up to 15%. Here's why

These high-beta healthcare stocks swing hard on catalysts.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Is the CSL share price heading to $200?

The healthcare giant is no longer dirt cheap, so I think further gains will need stronger support from earnings.

Read more »

Two brokers pointing and analysing a share price.
Healthcare Shares

CSL shares have surged over 25%. Do brokers see more upside?

CSL shares may keep climbing, but can earnings catch up?

Read more »